Clinical Trial Update: A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) [Phase 3]

View source ↗

Summary

Phase 3 study of ATB200/AT2221 in adults with late-onset Pompe disease has completed, with long-term safety and efficacy results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Late-onset Pompe Disease
• Pompe Disease

Drugs mentioned

• ATB200/AT2221

Snippet

Sponsor: Amicus Therapeutics | Conditions: Pompe Disease (Late-onset) | Phase 3 | Status: COMPLETED | Results posted: 2026-01-12